ArticleEuropean radiology2026
Plaque features for the prediction of in-stent restenosis in symptomatic intracranial atherosclerotic stenosis from a retrospective single-center study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular Therapy for Intracranial Atherosclerotic Stenosis: Evidence and Controversies.Journal of neuroendovascular therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis retrospective single-center study evaluates whether high-resolution magnetic resonance vessel wall imaging (HR-VWI) plaque features can predict in-stent restenosis (ISR) before stent implantation. MATERIALS AND
methodsConsecutive intracranial atherosclerotic disease (ICAD) patients undergoing HR-VWI and endovascular treatment from March 2018 to June 2024 were analyzed. ISR was defined as > 50% stenosis within or near (< 5 mm) the stent and > 20% absolute luminal loss. Multivariate logistic regression identified independent ISR risk factors, developing a prediction model and diagnostic nomogram. ISR-free survival was evaluated using Kaplan-Meier curves.
resultsAmong 217 patients (mean age 64.5 ± 10.2 years; 73.2% male), 50 (23.0%) developed ISR within 1 year. Plaque eccentricity (odds ratio (OR), 32.661; 95% confidence interval (CI): 3.726-286.334; p = 0.002), higher plaque-to-pituitary stalk contrast ratio (CR) (OR, 2.702; 95% CI: 1.098-6.649; p = 0.03), and lower lymphocyte-to-monocyte ratio (OR, 0.251; 95% CI: 0.106-0.594; p = 0.002) were independent ISR predictors. The model's AUC was 0.783 (95% CI: 0.683-0.883) for modeling and 0.827 (95% CI: 0.717-0.936) for validation, with a 0.3 cutoff. Kaplan-Meier analysis showed higher 12-month restenosis-free rates for patients with plaque eccentricity < 0.57 (68.5% vs. 27.7%; p < 0.001), CR < 38.22 (76.6% vs. 34.4%; p < 0.001) and lymphocyte-to-monocyte ratio ≥ 3.27 (70.4% vs. 37.6%; p < 0.001).
conclusionsIn symptomatic ICAD patients, ISR was linked to plaque eccentricity, elevated CR on HR-VWI, and reduced lymphocyte-to-monocyte ratio. These single-center findings may optimize therapeutic strategies and reduce restenosis risk, though further validation is needed to confirm their generalizability and reliability. KEY POINTS: Question Can clinical and imaging biomarkers predict in-stent restenosis (ISR) in symptomatic intracranial atherosclerotic stenosis (ICAD) to guide preprocedural risk stratification? Findings Plaque eccentricity, high plaque-to-pituitary stalk contrast ratio, and low lymphocyte-to-monocyte ratio independently predict ISR; our nomogram achieved 75% sensitivity and 82.6% specificity. Clinical relevance Preprocedural ISR prediction enables personalized strategies (e.g., stent optimization, targeted anti-inflammatory therapy), potentially reducing restenosis and stroke recurrence risk in ICAD patients undergoing stenting.
Indexed as
Identifiers
41269300What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.